Ravulizumab has been approved for a new indication in China, covering all patients with PNH.

According to Novartis Group's WeChat public account on May 29th, Novartis China announced that its oral monotherapy, Ravulizumab, has been approved by the National Medical Products Administration for the treatment of adults with paroxysmal nocturnal hemoglobinuria. This expansion of indication covers PNH patients who have previously received complement inhibitors. Ravulizumab now has three approved indications in China, including PNH adult patients who have not previously received complement inhibitors and adults with C3 glomerulonephritis.